Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04431908 · ClinicalTrials.gov registry record
Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 1,320
- Enrollment target
NCT04431908: Completed study, sponsored by Yale University.
NCT04431908 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 1,320 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04431908 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 1,320 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the performance of a non-invasive olfactory device as a rapid indicator of COVID-19 in positive subjects.
Primary Outcome
The subject's score on using the olfactory device will be compared to the PCR results (SARS-CoV-2 negative or positive) on COVID19 outpatients. As the smell test has a variable scale (0-5) the ideal cutoff will be determined to maximize these factors: * Sensitivity (Represents True Positives Divided by True Positives plus False Negatives) * Specificity (Represents True Negatives Divided by True Negatives plus False Positives) * Accuracy (Represents Sensitivity x Prevalence + Specificity x (1-Pr
Interventions
- DEVICE olfactory device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,320 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2020-11-18 |
What the finished NCT04431908 record still lists
NCT04431908 is an observational study that tracks outcomes without assigning an intervention. Its 1,320 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which olfactory device is the first listed.
NCT04431908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04431908 about?
NCT04431908 is a clinical study titled "Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects". The purpose of this study is to evaluate the performance of a non-invasive olfactory device as a rapid indicator of COVID-19 in positive subjects.
What is the current status of trial NCT04431908?
This trial is currently completed. The enrollment target is 1,320 participants. The study started on 2020-06-15. Estimated completion is 2020-11-18.
What interventions are being tested in trial NCT04431908?
The interventions under investigation include: olfactory device (DEVICE).
Who is sponsoring clinical trial NCT04431908?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06557005 · 1,320 participants · NA
Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions
- NCT07213908 · 1,320 participants · NA
Comparing Two School-Based Sleep Health Interventions To Promote Sleep Quality in Youth
- NCT07144800 · 1,319 participants · NA
Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
- NCT05097287 · 1,324 participants · Phase 4
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI